Jiangsu Kanion Pharmaceutical Co Ltd banner

Jiangsu Kanion Pharmaceutical Co Ltd
SSE:600557

Watchlist Manager
Jiangsu Kanion Pharmaceutical Co Ltd Logo
Jiangsu Kanion Pharmaceutical Co Ltd
SSE:600557
Watchlist
Price: 13.72 CNY -1.15%
Market Cap: ¥7.8B

Jiangsu Kanion Pharmaceutical Co Ltd
Investor Relations

In the bustling landscape of the Chinese pharmaceutical industry, Jiangsu Kanion Pharmaceutical Co Ltd emerges as a pivotal player, seamlessly blending centuries-old traditional Chinese medicine (TCM) with cutting-edge modern technology. Founded in 1975, the company has carved a niche for itself by focusing on the research, development, and production of both TCM and integrated Western medicine. Kanion is renowned for its innovative approach, transforming ancient herbal remedies into scientifically-backed therapeutic solutions. The company's approach is not just about preserving tradition but rather enhancing it, ensuring that products meet rigorous modern medical standards, thereby appealing to a broad spectrum of healthcare needs.

Kanion generates revenue through a diversified portfolio spanning herbal medicines, biochemical drugs, and health supplements. By implementing modern R&D methodologies, the company supports its vast array of products with robust clinical research, catering to both domestic and international markets. One of their key revenue streams is prescription medicines sold in hospitals and clinics, complemented by over-the-counter products available in pharmacies. Additionally, Kanion's investment in strategic partnerships and technological advancements has opened pathways for export, further amplifying its financial success. Through this blend of tradition and innovation, Jiangsu Kanion Pharmaceutical Co Ltd has established a resilient business model that thrives on the growing global acceptance of combining Eastern and Western medicinal practices.

Show more
Loading
600557
Shanghai Composite
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Mr. Yongchun Yang
GM & Director
No Bio Available
Mr. Suocheng Jiang
Deputy Chief Accountant, Accounting Supervisor, Financial Director & CFO
No Bio Available
Mr. Yu Pan
Deputy GM & Market Development Center
No Bio Available
Mr. Chuanlei Wang
Deputy General Manager
No Bio Available
Mr. Pan Peng
Secretary
No Bio Available

Contacts

Address
JIANGSU
Lianyungang
Jiangning Industrial Park, Economic & Technological Development Zone
Contacts
+8651885521990
www.kanion.com
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett